Droxidopa, also known by the brand name Northera, is a medication used to treat neurogenic orthostatic hypotension (NOH). Patients and researchers are often interested in the availability and cost of generic versions of this drug.
When might a generic version of Droxidopa become available?
The availability of a generic version of Droxidopa depends on patent expirations and any subsequent legal challenges. Information on patent status and expected generic entry dates can be found on sites like DrugPatentWatch.com [1]. Generally, once patents expire, other companies can apply to the U.S. Food and Drug Administration (FDA) to market generic alternatives, provided they demonstrate bioequivalence to the branded drug.
What is neurogenic orthostatic hypotension (NOH)?
NOH is a condition where a person's blood pressure drops significantly when they stand up, leading to symptoms like dizziness, lightheadedness, and fainting. This drop occurs due to a problem with the autonomic nervous system, which controls involuntary bodily functions like blood pressure regulation. Droxidopa works by converting into norepinephrine in the body, a neurotransmitter that helps constrict blood vessels and raise blood pressure [2].
How does Droxidopa work in the body?
Droxidopa is a synthetic amino acid precursor that acts as a prodrug. After administration, it is converted into norepinephrine, a potent vasoconstrictor. Norepinephrine then binds to adrenergic receptors, leading to increased vascular tone and an elevation in blood pressure. This mechanism helps to mitigate the symptoms of NOH [2].
What are the reported side effects of Droxidopa?
Common side effects associated with Droxidopa include supine hypertension (high blood pressure when lying down), headache, dizziness, nausea, and fatigue. It is important for patients to monitor their blood pressure in both upright and supine positions when taking this medication [3].
Who manufactures Droxidopa?
The branded drug Droxidopa (Northera) is manufactured by Lundbeck. The development and manufacturing of generic versions would typically be undertaken by other pharmaceutical companies following patent expiry [4].
What are the treatment options for NOH besides Droxidopa?
Treatment for NOH often involves lifestyle modifications such as increasing fluid and salt intake, wearing compression stockings, and avoiding triggers like prolonged standing or heat. Other medications may also be prescribed, including fludrocortisone and midodrine, which work through different mechanisms to help manage blood pressure [2].
How does Droxidopa compare to Midodrine?
Both Droxidopa and Midodrine are used to treat NOH by increasing blood pressure. Midodrine is an alpha-1 adrenergic agonist that directly constricts blood vessels. Droxidopa, as mentioned, is a prodrug that converts to norepinephrine. Clinical studies have compared the efficacy and safety of these agents, and the choice between them often depends on individual patient response, side effect profiles, and physician preference [2].
What is the typical cost of Droxidopa and its generic alternatives?
The cost of Droxidopa can be significant, particularly for the branded version. The introduction of generic alternatives typically leads to a substantial decrease in price, making the treatment more accessible. Exact pricing can vary based on pharmacy, insurance coverage, and the specific generic manufacturer [1].
Are there any clinical trials or studies involving Droxidopa?
Numerous clinical trials and studies have been conducted on Droxidopa to evaluate its efficacy, safety, and optimal use in patients with NOH. These studies contribute to the body of evidence supporting its use and can inform future treatment guidelines [2].
What is the regulatory status of Droxidopa?
Droxidopa is approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) for the treatment of symptomatic NOH associated with autonomic failure in adult patients. Generic versions require FDA approval, demonstrating that they meet the same safety and efficacy standards as the branded product [2].
Sources:
[1] DrugPatentWatch.com
[2] Information regarding neurogenic orthostatic hypotension and its treatment.
[3] Droxidopa prescribing information.
[4] Lundbeck company information.